No Data
No Data
Changchun High-Tech Industries (000661.SZ) pledged 20.83 million shares by the controlling shareholder.
Changchun High-Tech Industries (000661.SZ) announced that the company recently received a notice from its controlling shareholder, Changchun Chaoda Investment Group Co., Ltd ...
Changchun High-Tech Industries (000661.SZ) terminates the implementation of the 2022 restricted stock and stock option incentive plan.
Changchun High-Tech Industries (000661.SZ) has issued an announcement that the company has approved the "Termination of Implementation of Restriction in 2022..."
Changchun High-tech Industries (000661.SZ): The application for the listing of the controlled subsidiary's restructuring personnel promoting follicle-stimulating hormone-CTP fusion protein injection has been accepted.
On July 18th, Gelunhui reported that Changchun High-tech Industries (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as 'Jinsai Pharmaceutical'), recently received a 'Notice of Acceptance' issued by the National Drug Administration for the approved product - Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection. Infertility is a problem for childbearing couples in various countries and regions worldwide. With the decrease of birth population in recent years and the acceleration of population aging, the country has issued multiple policies to encourage childbirth. The huge population base has led to a huge demand for assisted reproduction technology. Jinsai Pharmaceutical is starting
Changchun High-Tech Industries (000661.SZ) has released its pledge on 5.15% of the company's shares held by its controlling shareholder.
Changchun High-Tech Industries (000661.SZ) announced that the company recently received a notice from its controlling shareholder, Changchun Chaoda Investment Group Co., Ltd ...
As of the end of March 2024, Changchun High-Tech Industries' subsidiary, High-Tech Real Estate, had total assets of 6.083 billion yuan and net assets of 2.471 billion yuan.
Changchun High-tech Industries (000661.SZ) stated on the investor platform that since its inception, the company has successfully transformed from focusing on high-tech zone infrastructure construction to becoming a conglomerate that focuses on pharmaceutical technology innovation and implements industrial investment. As of the end of March 2024, the total assets of the company's subsidiary, High-tech Real Estate, were 6.083 billion yuan, with a net asset of 2.471 billion yuan. Currently, the company actively monitors changes in the real estate industry, continues to focus on sales, strives to clear inventory, and accelerates the return of funds.
Changchun High-tech Industries (000661): Bullish about the transformation from single-product to diversified drive - In-depth report on Changchun High-tech Industries.
Investment highlights: We believe that 2024-2026 is a key window period for the company's growth curve transition. During this stage, the growth hormone products are expected to continue to maintain steady growth under the digestion of short-acting growth hormone joint procurement and the improvement of long-acting growth hormone penetration rate.
No Data